iRadimed (IRMD) vs LeMaitre Vascular (LMAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
iRadimed (IRMD) has outperformed LeMaitre Vascular (LMAT) over the past year, gaining 11.7% versus a loss of 9.5%. Over five years, IRMD leads with a +134.2% price change compared with +48.6% for LMAT. LeMaitre Vascular is the larger company by market cap ($1.84 billion vs $1.11 billion), about 1.7 times the size.
On valuation, LeMaitre Vascular trades at a lower forward P/E (25.4x vs 35.3x for iRadimed). LeMaitre Vascular offers the higher dividend yield (1.12% vs 0.89%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRMD | LMAT |
|---|---|---|
| Share price | $86.51 | $80.61 |
| Market cap | $1.11B | $1.84B |
| 1-day change | +0.73% | +1.22% |
| YTD return | -11.72% | -1.80% |
| 1-year return | +11.72% | -9.54% |
| 5-year return | +134.20% | +48.64% |
| P/E ratio (TTM) | 48.33 | 28.28 |
| Forward P/E | 35.26 | 25.36 |
| EPS (TTM) | $1.79 | $2.85 |
| Dividend yield | 0.89% | 1.12% |
| Annual dividend | $0.77 | $0.90 |
| Revenue (latest FY) | — | $249.60M |
| Revenue growth (YoY) | — | +13.53% |
| Net income (latest FY) | — | $57.73M |
| Gross margin | — | 71.53% |
| Operating margin | — | 27.21% |
| Net margin | — | 23.13% |
| 52-week high | $107.90 | $118.01 |
| 52-week low | $71.34 | $78.22 |
| Distance from 52-week high | -19.82% | -31.69% |
| Analyst consensus | none | buy |
| Avg. price target upside | +36.40% | +32.74% |
| Average volume | 125.83K | 330.14K |
| Shares outstanding | 12.79M | 22.87M |
| Employees | 166 | 646 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRMD has outperformed LMAT by 21.3 percentage points over the past year.
- iRadimed trades at a higher earnings multiple (48.3x vs 28.3x trailing P/E).
About iRadimed
IRMD stock →IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.
Health Care · Medical/Dental Instruments · 166 employees
About LeMaitre Vascular
LMAT stock →LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific.
Health Care · Medical/Dental Instruments · 646 employees
IRMD vs LMAT FAQ
Which is bigger, iRadimed or LeMaitre Vascular?
LeMaitre Vascular (LMAT) is larger, with a market capitalization of $1.84B compared with $1.11B for iRadimed (IRMD).
Which stock has performed better over the past year, IRMD or LMAT?
IRMD returned +11.72% over the past 12 months, compared with -9.54% for LMAT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, IRMD or LMAT?
LMAT has the lower trailing P/E at 28.3, versus 48.3 for IRMD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, iRadimed or LeMaitre Vascular?
LeMaitre Vascular has the higher yield at 1.12%, compared with 0.89% for iRadimed.
Are iRadimed and LeMaitre Vascular in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.